References of "Beckers, Albert"
     in
Bookmark and Share    
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (1993), 16(1-8), 137

Detailed reference viewed: 1 (0 ULg)
Peer Reviewed
See detailAspects cliniques de la néoplasie endocrinienne multiple de type 2 (NEM-2)
Moreau, L.; Beckers, Albert ULg

in Médecine & Chirurgie Digestives (1993), 23(1), 17-20

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailLocalisation scintigraphique de tumeurs neuroendocrines et de leurs métastases par un analogue de la somatostatine: [111In-DTPA-d-phe1] octréotide.
Beckers, Albert ULg; Pham, V. T.; Abs, R. et al

in Revue Médicale de Liège (1993), 48(6), 326-34

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailLe traitement des adénomes à prolactine : utilisation d'un nouvel agoniste dopaminergique à longue durée d'action, la cabergoline, chez 56 patients
Beckers, Albert ULg; Abs, R.; Demez, Pierre ULg et al

in Médecine et Hygiène (1993), 51(1990), 1978-1980

Nous avons utilisé la cabergoline, un nouvel agoniste dopaminergique, dans le traitement des adénomes hypophysaires à prolactine. Cinquante-six patients atteints de micro-adénome dans 35 cas et de ... [more ▼]

Nous avons utilisé la cabergoline, un nouvel agoniste dopaminergique, dans le traitement des adénomes hypophysaires à prolactine. Cinquante-six patients atteints de micro-adénome dans 35 cas et de macroadénome dans 21 cas ont été traités durant des périodes variant entre 1 et 17 mois à des doses de cabergoline variant entre 0,25 mg et 2 mg par semaine, prises à raison de 1 à 4 fois par semaine. Cette nouvelle substance nous est apparue extrêmement efficace et très bien tolérée [less ▲]

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailAspects cliniques de la neoplasie endocrinienne multiple de type 2 (NEM-2).
Moreau, L.; Beckers, Albert ULg

in Revue Médicale de Liège (1993), 48(6), 316-22

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAspects cliniques de la neoplasie endocrinienne multiple de type 1 (NEM-1).
Ghuysen, Alexandre ULg; Stevenaert, Achille ULg; Beckers, Albert ULg

in Revue Médicale de Liège (1993), 48(6), 309-63

Detailed reference viewed: 13 (1 ULg)
See detailDecreased number and defect of the initialization process of corticotropin-releasing hormone receptors in adenomatous corticotrophs
Smets, G.; Abs, R.; Verhelst, J. et al

in The 75th Annual meeting of the Endocrine society - Abstract book (1993)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailThe treatment of prolactinomas with cabergoline : results in 56 patients
Demez, Pierre ULg; Verhaert, G.; Stevenaert, Achille ULg et al

in Journal of Endocrinological Investigation (1993), 16

Detailed reference viewed: 5 (0 ULg)
See detailPresurgical octreotide treatment in acromegaly
Stevenaert, Achille ULg; Beckers, Albert ULg

in 3rd International pituitary congress - Abstract book (1993)

Detailed reference viewed: 2 (0 ULg)
See detailSerum GH response to the administration of TRh
Petrossians, Patrick ULg; Abs, R.; Beckers, Albert ULg

in Acta Clinica Belgica (1993), 48

Detailed reference viewed: 2 (0 ULg)
See detailThe treatment of prolactinomas with cabergoline : results in 56 patients
verhaert, g; demez, p; abs, r et al

in Acta Clinica Belgica (1993), (48),

Detailed reference viewed: 7 (0 ULg)
See detailACTH-Related peptide-secreting silent corticotroph adenomas of the pituitary
abs, r; Smets, G.; klöppel, G. et al

in Journal of Endocrinological Investigation (1993), 16

Detailed reference viewed: 5 (0 ULg)
See detailLight and Electron microscopic immunolocalization of Bovine pregnancy-associated glycoprotein in the Bovine Placentome
Demez, Pierre ULg; Zolli, A. P.; Beckers, Jean-François ULg et al

in 1st Joint meeting of the Royal Microscopical society and the Belgian Societies for Cell biology, clinical cytology, Electron Microscopy and pathology-Abstract book (1993)

Detailed reference viewed: 6 (0 ULg)
Peer Reviewed
See detailDecreased number and defect of the internalization process of corticotropin-releasing hormone receptors in adenomatous corticotrophs
verhelst, j; Abs, R.; Beckers, Albert ULg et al

in Acta Clinica Belgica (1993), 48

Detailed reference viewed: 2 (0 ULg)
See detailThe treatment of prolactinomas with cabegoline : results in 56 patients
Verhelst, J.; Abs, R.; Verhaert, G. et al

in Neuro-endocrinologie PRL, VI International prolactin congress - Abstract book (1993)

Detailed reference viewed: 11 (0 ULg)
Peer Reviewed
See detailEngery-filtering transmission electron microscopy of biological specimens.
de Bruijn, W. C.; Sorber, C. W.; Gelsema, E. S. et al

in Scanning Microscopy (1993), 7(2), 693-708709

By energy-filtering transmission electron microscopy (EFTEM) electrons can be separated by their energy losses. An electron-energy filter, added to the microscope column allows the measurement of the ... [more ▼]

By energy-filtering transmission electron microscopy (EFTEM) electrons can be separated by their energy losses. An electron-energy filter, added to the microscope column allows the measurement of the energy distribution of transmitted electrons that have lost energy (< 2,000 eV, with an energy resolution of approximately 1 eV). These filtered electrons, recorded either as a spectrum or as an image, are composed of two parts superimposed on top of each other: (a) the unspecific energy-loss population (= the continuum) and (b) the specific element-related energy-loss population (= the edges). At the edges, electron data in spectra and images are mathematically processed, to obtain the desired element-related net-intensity values or images. These data are related to the total transmitted electron intensity, from the zero- and low-loss spectral region giving the relative spectralor image intensity rations ((S)R*x, (I)R*x), which can be related to the element concentration. The acquisition of the zero-loss and low-loss data is hampered by the restricted dynamic range of the TV camera. By improvements through the introduction of calibrated attenuation filters in the optical path to the TV-camera, more reliable values for (S)R*x and (I)R*x can be acquired. By addition of Bio-standards adjacent to the tissue, a "known" and "unknown" concentration of the element present in the same ultrathin section and the "bias" in the concentration estimation, can be obtained. Some practical examples are given for the estimation of the iron cencentration in siderosomes, boron in melasosomes and calcium in calcium oxalate monohydrate crystals. [less ▲]

Detailed reference viewed: 16 (0 ULg)
Peer Reviewed
See detailAspects cliniques de la néoplasie endocrinienne multiple de type 1 (NEM-1)
Ghuysen, Alexandre ULg; Beckers, Albert ULg; Stevenaert, Achille ULg

in Médecine & Chirurgie Digestives (1993), 22(8), 468-470

Detailed reference viewed: 13 (0 ULg)
See detailAcromégalie et grossesse : évolution des hormones de croissance hypophysaires et placentaires
Beckers, Albert ULg

Scientific conference (1992, December 12)

Detailed reference viewed: 13 (1 ULg)
Peer Reviewed
See detailPresurgical octreotide treatment in acromegaly.
Stevenaert, Achille ULg; Harris, A. G.; Kovacs, K. et al

in Metabolism : Clinical and Experimental (1992), 41(9 Suppl. 2), 51-8

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered ... [more ▼]

The aim of this study was to determine the role of octreotide administration in acromegalic patients as a preparation for selective adenomectomy using transsphenoidal route. Octreotide was administered for 3 to 6 weeks before surgery in 12 patients and for 4 to 39 months in 25 patients. The clinical response was judged as excellent or good in 10 of 12 patients from group I and in 23 of 25 patients from group II. Marked reduction (ie, greater than 50% of initial values) in serum growth hormone (GH) levels was seen in all patients, with levels to less than 5 micrograms/L in 68% of patients and less than 2 micrograms/L in 27%. Insulin-like growth factor 1 (IGF-1) levels decreased to within normal limits in half the cases. During long-term treatment, an escape phenomenon could be seen. Varying degrees of tumor shrinkage were seen in more than 50% of cases. During surgery, with regard to the relative ease or difficulty in removing the tumor, the consistency of the tumor and the separation of normal from pathological tissue, no significant difference was observed between patients given octreotide and those from control series. Morphological changes in adenomatous tissue were rather small. The surgical outcome was similar in the pretreated series as in the control series, except in enclosed adenomas, which showed a tendency to a higher success rate. Since octreotide improves both the clinical condition and hormonal parameters and induces varying degrees of tumor shrinkage, it is potentially useful as an adjunct to surgery. Morphological data suggest that octreotide exercises a functional inhibitory effect on GH release. [less ▲]

Detailed reference viewed: 11 (1 ULg)